Quarterly ResultMay 12, 2026, 08:12 AM
Kalaris Q1 Net Loss $10.9M; Cash $104.9M; Clinical Trials Progress
AI Summary
Kalaris Therapeutics reported a net loss of $10.9 million for the first quarter ended March 31, 2026. The company held $104.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the fourth quarter of 2027. Kalaris also provided business updates, confirming that patient screening is underway for its Phase 1b/2 study of TH103, with preliminary data anticipated in the first half of 2027, and planned Phase 3 clinical trials on track for year-end 2027 initiation.
Key Highlights
- Net loss for Q1 2026 was $10.9 million, compared to $10.2 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $104.9 million as of March 31, 2026.
- Cash runway is expected to fund operations into the fourth quarter of 2027.
- Research and development expenses increased to $7.6 million in Q1 2026 from $6.0 million in Q1 2025.
- Patient screening is underway for the Phase 1b/2 study of TH103 for neovascular Age-related Macular Degeneration.
- Preliminary data from the Phase 1b/2 study is expected in the first half of 2027.
- Planned Phase 3 clinical trials remain on track for 2027 year-end initiation.